SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VAXGEN INC. (VXGN)- The IPO -- Ignore unavailable to you. Want to Upgrade?

To: Manfred Sondermann who wrote (35)7/12/1999 9:03:00 AM
From: gary r. albrecht  Read Replies (1) | Respond to of 55
 
Manfred, I think you are correct in that Genentech is the holder of the patents. However, Vaxgen has an exclusive license from Genetech to the patents. Genentech can terminate the license agreement under certain non-performance clauses.

GPSite, I realize that statistical results from those vaccinated in Phases I and II would not be valid for use by the FDA. I am only speaking with regard to my investment comfort level. If I knew that not one of the 2000 vaccinated have become infected with HIV my comfort level would be greater, that is all I'm getting at.

gary



To: Manfred Sondermann who wrote (35)7/12/1999 12:55:00 PM
From: glen  Respond to of 55
 
VXGN continues to make newer highs, hitting 22 1/2 today!! Genentech is the parent company of VaxGen and both will share the rewards if AIDVAX becomes the first FDA approved AIDS vaccine. VaxGen, though, will be the pure play on the vaccine. It will provide the greatest leverage, in terms of the risk/reward return, for the investor who believes in the eventual success of AIDSVAX.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News